Jerald P. Radich, MD

Articles

Dr. Radich on the Impact of MRD on Survival Outcomes in AML

April 30th 2021

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Dr. Radich on Measuring MRD in Hematologic Malignancies

May 23rd 2020

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Dr. Radich on the Utility of MRD in Hematologic Malignancies

March 28th 2020

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Dr. Radich on Impact of MRD in Acute Vs Chronic Leukemias

March 25th 2020

Jerald P. Radich, MD, discusses the impact of minimal residual disease in patients with acute versus chronic leukemias.

Dr. Radich on the Evolving Role of MRD in Hematologic Malignancies

March 1st 2020

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

Dr. Radich on Compliance to NCCN Guidelines in CML

October 12th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Dr. Radich on Treatment Discontinuation in CML Off Trial

September 28th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

Dr. Radich on the Potential of Biosimilars in Oncology

September 25th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.

Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML

October 8th 2016

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).

Dr. Jerald Radich on Impact of Generic Imatinib in CML

October 1st 2016

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).